ALVOW
Alvotech
Price Chart
Latest Quote
$0.42
Current Price| Previous Close | $0.43 |
| Open | $1.98 |
| Day High | $0.45 |
| Day Low | $0.42 |
| Volume | 2,276 |
Stock Information
| Total Debt | $1.28B |
| Cash Equivalents | $42.85M |
| Revenue | $573.35M |
| Net Income | $69.50M |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 18/42| Debt to Equity | -2.88 |
| Debt to Earnings | 3.91 |
| Current Ratio | 2.35 |
| Quick Ratio | 1.57 |
| Avg Revenue Growth | 307.92% |
| Profit Margin | -47.35% |
| Return on Equity | 56.17% |
| Avg FCF Growth | 2.33% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.42 | 2,276 |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
📰 Latest News
Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates
Zacks • 2025-11-12T22:55:02Z
European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown
MT Newswires • 2025-11-10T17:22:14ZAlvotech (ALVO) Is Down 35.5% After FDA Delays Key AVT05 Biosimilar Approval—Has The Bull Case Changed?
Simply Wall St. • 2025-11-07T18:12:48Z
Can Alvotech’s Sharp 61% Drop Signal a Value Opportunity After Regulatory Updates?
Simply Wall St. • 2025-11-07T11:12:43Z
How Recent Developments Are Rewriting the Story for Alvotech
Simply Wall St. • 2025-11-07T02:09:24Z
Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for
Zacks • 2025-11-05T15:00:02Z
Alvotech (NASDAQ:ALVO) Analysts Just Slashed This Year's Revenue Estimates By 11%
Simply Wall St. • 2025-11-05T11:00:11Z
Alvotech faces FDA setback for its Simponi biosimilar AVT05
Pharmaceutical Technology • 2025-11-04T07:00:00Z
A Fresh Look at Alvotech (NasdaqGM:ALVO) Valuation Following Recent Share Price Decline
Simply Wall St. • 2025-11-03T23:12:56Z
Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell
MT Newswires • 2025-11-03T11:13:57ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $158,267,000 | $140,167,000 | $47,040,000 | $0 |
| Cost Of Revenue | $185,309,000 | $160,856,000 | $64,095,000 | $0 |
| Total Revenue | $489,682,000 | $91,434,000 | $83,029,000 | $36,772,000 |
| Operating Revenue | $489,682,000 | $91,434,000 | $83,029,000 | $36,772,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $153,987,000 | $133,167,000 | $77,474,000 | $112,971,000 |
| Total Expenses | $420,038,000 | $446,294,000 | $429,471,000 | $272,228,000 |
| Other Income Expense | $-134,223,000 | $-166,188,000 | $-114,679,000 | $200,796,000 |
| Net Non Operating Interest Income Expense | $-152,984,000 | $-130,001,000 | $-90,526,000 | $-114,538,000 |
| Total Other Finance Cost | $3,614,000 | $1,657,000 | $13,964,000 | $1,586,000 |
| Interest Expense Non Operating | $153,987,000 | $133,167,000 | $77,474,000 | $112,971,000 |
| Operating Expense | $234,729,000 | $285,438,000 | $365,376,000 | $272,228,000 |
| Other Operating Expenses | $-2,296,000 | $-1,948,000 | $-1,988,000 | $-2,912,000 |
| General And Administrative Expense | $61,454,000 | $73,038,000 | $183,388,000 | $84,134,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Net Interest Income | $-152,984,000 | $-130,001,000 | $-90,526,000 | $-114,538,000 |
| Interest Income | $4,617,000 | $4,823,000 | $912,000 | $19,000 |
| Normalized Income | $-125,827,830 | $-416,956,905 | $-409,225,141 | $-239,689,520 |
| Net Income From Continuing And Discontinued Operation | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Total Operating Income As Reported | $69,644,000 | $-354,860,000 | $-346,442,000 | $-235,456,000 |
| Net Income Common Stockholders | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Net Income | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Net Income Including Noncontrolling Interests | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Net Income Continuous Operations | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Pretax Income | $-217,563,000 | $-651,049,000 | $-551,647,000 | $-149,198,000 |
| Special Income Charges | $-72,348,000 | $-21,519,000 | $-27,311,000 | $151,788,000 |
| Earnings From Equity Interest | $0 | $-7,153,000 | $-2,590,000 | $-2,418,000 |
| Interest Income Non Operating | $4,617,000 | $4,823,000 | $912,000 | $19,000 |
| Operating Income | $69,644,000 | $-354,860,000 | $-346,442,000 | $-235,456,000 |
| Depreciation Amortization Depletion Income Statement | $4,259,000 | $3,521,000 | $3,354,000 | - |
| Depreciation And Amortization In Income Statement | $4,259,000 | $3,521,000 | $3,354,000 | - |
| Gross Profit | $304,373,000 | $-69,422,000 | $18,934,000 | $36,772,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-28,186,830 | $-24,260,905 | $-7,734,141 | $65,028,480 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $101,948,000 | $-334,637,000 | $-341,675,000 | $-221,245,000 |
| Total Unusual Items | $-134,223,000 | $-159,035,000 | $-112,089,000 | $203,214,000 |
| Total Unusual Items Excluding Goodwill | $-134,223,000 | $-159,035,000 | $-112,089,000 | $203,214,000 |
| Reconciled Depreciation | $31,301,000 | $24,210,000 | $20,409,000 | $18,196,000 |
| EBITDA (Bullshit earnings) | $-32,275,000 | $-493,672,000 | $-453,764,000 | $-18,031,000 |
| EBIT | $-63,576,000 | $-517,882,000 | $-474,173,000 | $-36,227,000 |
| Diluted NI Availto Com Stockholders | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Tax Provision | $14,301,000 | $-99,318,000 | $-38,067,000 | $-47,694,000 |
| Gain On Sale Of Business | $-2,970,000 | $0 | $0 | - |
| Other Special Charges | $69,378,000 | - | $27,311,000 | $-151,788,000 |
| Write Off | $0 | $21,519,000 | $0 | $0 |
| Gain On Sale Of Security | $-61,875,000 | $-137,516,000 | $-84,778,000 | $51,426,000 |
| Research And Development | $171,312,000 | $210,827,000 | $180,622,000 | $191,006,000 |
| Selling General And Administration | $61,454,000 | $73,038,000 | $183,388,000 | $84,134,000 |
| Other Gand A | $22,321,000 | $29,376,000 | $143,411,000 | $84,134,000 |
| Salaries And Wages | $39,133,000 | $43,662,000 | $39,977,000 | - |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-444,722,000 | $-963,627,000 | $-601,711,000 | $-169,488,000 |
| Total Assets | $1,221,400,000 | $950,090,000 | $828,443,000 | $597,977,000 |
| Total Non Current Assets | $766,380,000 | $755,248,000 | $597,707,000 | $478,161,000 |
| Other Non Current Assets | $3,615,000 | $28,376,000 | $30,967,000 | $11,750,000 |
| Non Current Deferred Assets | $298,360,000 | $309,807,000 | $209,496,000 | $170,418,000 |
| Non Current Deferred Taxes Assets | $298,360,000 | $309,807,000 | $209,496,000 | $170,418,000 |
| Non Current Accounts Receivable | $22,710,000 | $10,856,000 | $3,286,000 | $1,479,000 |
| Goodwill And Other Intangible Assets | $31,951,000 | $31,134,000 | $37,295,000 | $33,876,000 |
| Other Intangible Assets | $20,621,000 | $19,076,000 | $25,652,000 | $21,509,000 |
| Current Assets | $455,020,000 | $194,842,000 | $230,736,000 | $119,816,000 |
| Prepaid Assets | $23,984,000 | $22,035,000 | $20,601,000 | $9,320,000 |
| Inventory | $127,889,000 | $74,433,000 | $71,470,000 | $39,058,000 |
| Receivables | $251,719,000 | $87,217,000 | $71,387,000 | $53,882,000 |
| Other Receivables | $73,665,000 | $36,228,000 | $30,399,000 | $18,650,000 |
| Taxes Receivable | $17,719,000 | $8,801,000 | $6,468,000 | $4,725,000 |
| Accounts Receivable | $160,217,000 | $41,292,000 | $32,972,000 | $29,396,000 |
| Cash Cash Equivalents And Short Term Investments | $51,428,000 | $11,157,000 | $66,427,000 | $17,556,000 |
| Cash And Cash Equivalents | $51,428,000 | $11,157,000 | $66,427,000 | $17,556,000 |
| Hedging Assets Current | - | $0 | $851,000 | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $1,017,156,000 | $949,002,000 | $698,143,000 | $383,355,000 |
| Total Debt | $1,190,236,000 | $1,075,474,000 | $805,102,000 | $523,051,000 |
| Long Term Debt And Capital Lease Obligation | $1,148,019,000 | $1,027,766,000 | $780,023,000 | $512,985,000 |
| Long Term Debt | $1,035,882,000 | $922,134,000 | $744,654,000 | $398,140,000 |
| Current Debt And Capital Lease Obligation | $42,217,000 | $47,708,000 | $25,079,000 | $10,066,000 |
| Current Debt | $32,702,000 | $38,025,000 | $19,916,000 | $2,771,000 |
| Other Current Borrowings | $32,702,000 | $38,025,000 | $19,916,000 | $2,771,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $1,634,171,000 | $1,882,583,000 | $1,392,859,000 | $733,589,000 |
| Total Non Current Liabilities Net Minority Interest | $1,440,775,000 | $1,621,633,000 | $1,225,565,000 | $621,753,000 |
| Derivative Product Liabilities | $210,224,000 | $520,553,000 | $380,232,000 | $0 |
| Non Current Deferred Liabilities | $82,532,000 | $73,314,000 | $57,326,000 | $44,994,000 |
| Non Current Deferred Taxes Liabilities | $1,811,000 | $53,000 | $309,000 | $150,000 |
| Current Liabilities | $193,396,000 | $260,950,000 | $167,294,000 | $111,836,000 |
| Current Deferred Liabilities | $15,980,000 | $59,183,000 | $36,915,000 | $29,692,000 |
| Payables And Accrued Expenses | $128,568,000 | $147,325,000 | $87,842,000 | $72,078,000 |
| Interest Payable | $428,000 | $3,333,000 | $2,249,000 | $7,547,000 |
| Payables | $75,795,000 | $91,339,000 | $51,253,000 | $37,566,000 |
| Total Tax Payable | $204,000 | $925,000 | $934,000 | $841,000 |
| Accounts Payable | $67,126,000 | $80,563,000 | $49,188,000 | $28,587,000 |
| Tradeand Other Payables Non Current | - | $0 | $0 | $0 |
| Other Payable | - | - | - | $7,500,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-412,771,000 | $-932,493,000 | $-564,416,000 | $-135,612,000 |
| Total Equity Gross Minority Interest | $-412,771,000 | $-932,493,000 | $-564,416,000 | $-135,612,000 |
| Stockholders Equity | $-412,771,000 | $-932,493,000 | $-564,416,000 | $-135,612,000 |
| Gains Losses Not Affecting Retained Earnings | $15,054,000 | $41,383,000 | $29,140,000 | $4,669,000 |
| Other Equity Adjustments | $17,272,000 | $42,911,000 | $30,582,000 | - |
| Retained Earnings | $-2,437,709,000 | $-2,205,845,000 | $-1,654,114,000 | $-1,140,534,000 |
| Long Term Equity Investment | $0 | $18,494,000 | $48,568,000 | $55,307,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $22,995,363 | $22,905,618 | - | - |
| Ordinary Shares Number | $301,805,677 | $266,821,844 | $248,649,506 | $243,649,505 |
| Share Issued | $324,801,040 | $289,727,462 | $248,649,506 | $243,649,505 |
| Tangible Book Value | $-444,722,000 | $-963,627,000 | $-601,711,000 | $-169,488,000 |
| Invested Capital | $655,813,000 | $27,666,000 | $200,154,000 | $265,299,000 |
| Working Capital | $261,624,000 | $-66,108,000 | $63,442,000 | $7,980,000 |
| Capital Lease Obligations | $121,652,000 | $115,315,000 | $40,532,000 | $122,140,000 |
| Total Capitalization | $623,111,000 | $-10,359,000 | $180,238,000 | $262,528,000 |
| Foreign Currency Translation Adjustments | $-2,218,000 | $-1,528,000 | $-1,442,000 | $4,669,000 |
| Additional Paid In Capital | $2,007,058,000 | $1,229,690,000 | $1,058,432,000 | $1,000,118,000 |
| Capital Stock | $2,826,000 | $2,279,000 | $2,126,000 | $135,000 |
| Common Stock | $2,826,000 | $2,279,000 | $2,126,000 | $135,000 |
| Non Current Deferred Revenue | $80,721,000 | $73,261,000 | $57,017,000 | $44,844,000 |
| Long Term Capital Lease Obligation | $112,137,000 | $105,632,000 | $35,369,000 | $114,845,000 |
| Current Deferred Revenue | $15,980,000 | $59,183,000 | $36,915,000 | $29,692,000 |
| Current Capital Lease Obligation | $9,515,000 | $9,683,000 | $5,163,000 | $7,295,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,631,000 | $6,734,000 | $17,458,000 | - |
| Current Accrued Expenses | $52,773,000 | $55,986,000 | $36,589,000 | $34,512,000 |
| Dueto Related Parties Current | $8,465,000 | $9,851,000 | $1,131,000 | $638,000 |
| Investments And Advances | $0 | $18,494,000 | $48,568,000 | $55,307,000 |
| Investmentsin Joint Venturesat Cost | $0 | $18,494,000 | $48,568,000 | $55,307,000 |
| Goodwill | $11,330,000 | $12,058,000 | $11,643,000 | $12,367,000 |
| Net PPE | $409,744,000 | $356,581,000 | $268,095,000 | $205,331,000 |
| Accumulated Depreciation | $-84,614,000 | $-68,129,000 | $-51,113,000 | $-43,926,000 |
| Gross PPE | $494,358,000 | $424,710,000 | $319,208,000 | $249,257,000 |
| Other Properties | $124,930,000 | $119,413,000 | $47,162,000 | $126,642,000 |
| Machinery Furniture Equipment | $369,428,000 | $305,297,000 | $272,046,000 | $122,615,000 |
| Inventories Adjustments Allowances | $-6,920,000 | $-10,403,000 | $-2,062,000 | $-1,262,000 |
| Finished Goods | $0 | $244,000 | $2,121,000 | $0 |
| Work In Process | $81,243,000 | $33,068,000 | $29,450,000 | $13,730,000 |
| Raw Materials | $53,566,000 | $51,524,000 | $41,961,000 | $26,590,000 |
| Duefrom Related Parties Current | $118,000 | $896,000 | $1,548,000 | $1,111,000 |
| Employee Benefits | - | $0 | $544,000 | $56,334,000 |
| Dueto Related Parties Non Current | - | $0 | $7,440,000 | $7,440,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-293,843,000 | $-358,658,000 | $-361,391,000 | $-268,803,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-236,843,000 | $-312,185,000 | $-312,389,000 | $-228,170,000 |
| Cash Flow From Continuing Operating Activities | $-236,843,000 | $-312,185,000 | $-312,389,000 | $-228,170,000 |
| Operating Gains Losses | $-5,191,000 | $12,701,000 | $-12,779,000 | $-49,008,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-57,000,000 | $-46,473,000 | $-49,002,000 | $-40,633,000 |
| Investing Cash Flow | $-18,868,000 | $-46,340,000 | $-63,537,000 | $-40,633,000 |
| Cash Flow From Continuing Investing Activities | $-18,868,000 | $-46,340,000 | $-63,537,000 | $-40,633,000 |
| Net Other Investing Changes | $26,132,000 | - | $-14,914,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $150,451,000 | $136,879,000 | $9,827,000 | $185,856,000 |
| Financing Cash Flow | $297,306,000 | $301,319,000 | $424,910,000 | $254,831,000 |
| Cash Flow From Continuing Financing Activities | $297,306,000 | $301,319,000 | $424,910,000 | $254,831,000 |
| Net Other Financing Charges | $-10,048,000 | $-13,145,000 | $157,266,000 | - |
| Net Common Stock Issuance | $150,451,000 | $136,879,000 | $9,827,000 | $185,856,000 |
| Common Stock Issuance | $150,451,000 | $136,879,000 | $9,827,000 | $185,856,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-768,779,000 | $-107,636,000 | $-95,861,000 | $-44,846,000 |
| Issuance Of Debt | $920,763,000 | $278,831,000 | $353,678,000 | $113,821,000 |
| End Cash Position | $51,428,000 | $11,157,000 | $66,427,000 | $17,556,000 |
| Beginning Cash Position | $11,157,000 | $66,427,000 | $17,556,000 | $31,689,000 |
| Effect Of Exchange Rate Changes | $-1,324,000 | $1,936,000 | $-113,000 | $-161,000 |
| Changes In Cash | $41,595,000 | $-57,206,000 | $48,984,000 | $-13,972,000 |
| Proceeds From Stock Option Exercised | $4,919,000 | $6,390,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $151,984,000 | $171,195,000 | $257,817,000 | $68,975,000 |
| Net Short Term Debt Issuance | $-9,500,000 | $0 | $-50,000,000 | $0 |
| Short Term Debt Payments | $-9,500,000 | $0 | $-50,000,000 | $0 |
| Net Long Term Debt Issuance | $161,484,000 | $171,195,000 | $307,817,000 | $68,975,000 |
| Long Term Debt Payments | $-759,279,000 | $-107,636,000 | $-45,861,000 | $-44,846,000 |
| Long Term Debt Issuance | $920,763,000 | $278,831,000 | $353,678,000 | $113,821,000 |
| Net Business Purchase And Sale | $12,000,000 | $0 | $0 | $0 |
| Sale Of Business | $12,000,000 | $0 | $0 | - |
| Net Intangibles Purchase And Sale | $-3,339,000 | $-13,239,000 | $-11,122,000 | $-20,171,000 |
| Purchase Of Intangibles | $-3,339,000 | $-13,239,000 | $-11,122,000 | $-20,171,000 |
| Net PPE Purchase And Sale | $-53,661,000 | $-33,101,000 | $-37,501,000 | $-20,462,000 |
| Sale Of PPE | $0 | $133,000 | $379,000 | $0 |
| Purchase Of PPE | $-53,661,000 | $-33,234,000 | $-37,880,000 | $-20,462,000 |
| Taxes Refund Paid | $-2,037,000 | $-1,354,000 | $-834,000 | $-155,000 |
| Interest Received Cfo | $4,617,000 | $3,649,000 | $568,000 | $16,000 |
| Interest Paid Cfo | $-54,921,000 | $-57,254,000 | $-35,372,000 | $-28,004,000 |
| Change In Working Capital | $-288,644,000 | $26,328,000 | $-47,890,000 | $-6,807,000 |
| Change In Other Working Capital | $-31,446,000 | $35,396,000 | $19,396,000 | $21,470,000 |
| Change In Other Current Liabilities | $-22,170,000 | $-3,902,000 | $-20,891,000 | $4,707,000 |
| Change In Other Current Assets | $-7,125,000 | $-802,000 | $-17,194,000 | $-4,363,000 |
| Change In Payables And Accrued Expense | $-13,695,000 | $31,772,000 | $16,442,000 | $14,318,000 |
| Change In Payable | $-13,695,000 | $31,772,000 | $16,442,000 | $14,318,000 |
| Change In Inventory | $-49,973,000 | $-11,304,000 | $-32,412,000 | $-29,412,000 |
| Change In Receivables | $-164,235,000 | $-24,832,000 | $-13,231,000 | $-13,527,000 |
| Changes In Account Receivables | $-119,063,000 | $-8,320,000 | $-3,576,000 | $-28,813,000 |
| Other Non Cash Items | $292,398,000 | $262,412,000 | $302,084,000 | $-19,295,000 |
| Stock Based Compensation | $7,626,000 | $18,033,000 | $10,317,000 | $0 |
| Provisionand Write Offof Assets | $-4,429,000 | $26,841,000 | $0 | $0 |
| Asset Impairment Charge | $0 | $23,298,000 | $2,755,000 | $6,085,000 |
| Deferred Tax | $14,301,000 | $-99,318,000 | $-38,067,000 | $-47,694,000 |
| Deferred Income Tax | $14,301,000 | $-99,318,000 | $-38,067,000 | $-47,694,000 |
| Depreciation Amortization Depletion | $31,301,000 | $24,210,000 | $20,409,000 | $18,196,000 |
| Depreciation And Amortization | $31,301,000 | $24,210,000 | $20,409,000 | $18,196,000 |
| Earnings Losses From Equity Investments | $0 | $7,153,000 | $2,590,000 | $2,418,000 |
| Net Foreign Currency Exchange Gain Loss | $-8,161,000 | $5,183,000 | $-10,566,000 | $-2,681,000 |
| Gain Loss On Sale Of PPE | $0 | $365,000 | $0 | $0 |
| Gain Loss On Sale Of Business | $2,970,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 |
| Short Term Debt Issuance | - | $0 | $160,000,000 | $0 |
| Gain Loss On Investment Securities | - | $132,333,000 | $95,344,000 | $-48,745,000 |
| Purchase Of Business | - | - | - | $0 |
| Change In Account Payable | - | - | - | $14,318,000 |